SCHEMBL6397198

SCHEMBL6397198

O=C(CCCc1ccc(O)cc1)c1c(O)cc(O)cc1P(=O)(O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.66
SGMS1 Q86VZ5 2/20 0.66
SGMS2 Q8NHU3 2/20 0.66
SLC5A1 P13866 7/20 0.60
SLC5A2 P31639 7/20 0.60
CYP19A1 P11511 3/20 0.60
SLC28A3 Q9HAS3 3/20 0.60
GAA P10253 2/20 0.60
MAPT P10636 2/20 0.60
NFKB1 P19838 2/20 0.60
NFKB2 Q00653 2/20 0.60
RELA Q04206 2/20 0.60
KDM4E B2RXH2 1/20 0.60
MEN1 O00255 1/20 0.60
SLC16A3 O15427 1/20 0.60
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
TTR P02766 1/20 0.60
ESR1 P03372 1/20 0.60
TP53 P04637 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6399875 0.92 SLC5A1 (0.72) ACHESGMS1SGMS2SLC5A1SLC5A2
SCHEMBL6397103 0.86 CBS (0.53) ACHESGMS1SGMS2SLC5A1SLC5A2
SCHEMBL28895928 0.85 ACHE (0.88) ACHESGMS1SGMS2SLC5A1SLC5A2
SCHEMBL6401949 0.84 ACHE (0.66) ACHESGMS1SGMS2SLC5A1SLC5A2
SCHEMBL6396380 0.83 MAPT (0.56) ACHESGMS1SGMS2SLC5A1SLC5A2
SCHEMBL6403797 0.81 MEN1 (0.48) ACHESGMS1SGMS2SLC5A1SLC5A2
SCHEMBL6397193 0.81 ACHE (0.61) ACHESGMS1SGMS2SLC5A1SLC5A2
SCHEMBL6397107 0.81 ACHE (0.61) ACHESGMS1SGMS2SLC5A1SLC5A2
Phloretin SCHEMBL27889444 0.80 SLC5A1 (0.87) ACHESGMS1SGMS2SLC5A1SLC5A2
SCHEMBL6396379 0.78 ACHE (0.47) ACHESGMS1SGMS2SLC5A1SLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ACHE 4865/4885SGMS1 4101/4885SGMS2 4281/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.